Medinfo - Find - James W Lynch

Please note that Find will be retiring soon. Directory functionality will be replaced by the new UF Health Directory. If you have any questions about the Find retirement you can contact us here.


Oncology Course Director, Faculty, Medicine

Complete Name: James W Lynch, Jr, M.D.

Phones:UF Business Telephone: (352) 273-7990

Shands Provider Number: (352) 265-0725

Postal:UF Business Mailing
    Po Box 100216
    Gainesville, FL 326100216



Medical School
Eastern Virginia Medical School, Norfolk, VA 1984

University of Florida College of Medicine, Gainesville, FL 1987

National Cancer Institute

  • Lynch JW.  A Piece of My Mind: Regaining Compassion, JAMA, May 13, 1998, 279(18):1422
  • Lucio Gordan, William B. Grow, Raul C. Braylan, Nancy P. Mendenhall, Vonda Douglas, Annette Pusateri, Lakshmi Balasubramanian, James W. Lynch. Phase II Trial of Individualized Pharmacokinetic Dosing of Rituximab Maintenance for Patients with CD-20 Positive Lymphoproliferative Disorders. J Clin Oncol. 2005 Feb 20;23(6):1096-102
  • Walsh K, Lynch JW, Al-Quran S, Li Y and Braylan R.  Discordant Expression of CD20 by Flow Cytometry and Immunohistochemistry in a Patient Responding to Rituximab:  An Unusual Mechanism.  Clin Lymphoma Myeloma. 2007 Jan;7(4):319-22.
  • Chera B, Olivier K, Morris C, Lynch J, Mendenhall M.  Clinical Presentation and Outcomes of Lymphocyte-predominant Hodgkin’s Disease at the University of Florida:  Am J Clin Oncol. 2007 Dec; 30(6):601-6.
  • Advancing Educators and Education: Defining the Components and Evidence of Educational Scholarship.  AAMC Group on Educational Affairs Consensus Conference on Educational Scholarship.  2007
  • Daniel T. Chang, MD; Nancy P. Mendenhall, MD; James W. Lynch, MD; Christopher G. Morris, MS; Kenneth R. Olivier, MD. Long-term outcomes for stage I-II aggressive non-Hodgkin’s lymphoma of Waldeyer’s ring: Am J Clin Oncol. 2009 Jun;32(3):233-7
  • James W Lynch MD; Information Overload and the Need for Wisdom: A Medical Perspective: Reconsiderations Vol 9 No 1. December 2009
  • Effective Dose Reduction to Cardiac Structures Using Protons Compared with 3DCRT and IMRT in Mediastinal Hodgkin Lymphoma.Hoppe BS, Flampouri S, Su Z, Latif N, Dang NH, Lynch J, Joyce M, Sandler E, Li Z, Mendenhall NP.Int J Radiat Oncol Biol Phys. 2012 Mar 2. [Epub ahead of print].
  • Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study.Hoppe BS, Flampouri S, Su Z, Morris CG, Latif N, Dang NH, Lynch J, Li Z, Mendenhall NP.
  • Outcomes of patients with non-Hodgkin's lymphoma treated with Bexxar with or without external-beam radiotherapy.Smith K, Byer G, Morris CG, Kirwan JM, Lightsey J, Mendenhall NP, Hoppe BS, Lynch J, Olivier K.Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1122-7.

  • Medical Education
  • Experimental therapeutics and prognostic factors for Hodgkin's and Non-Hodgkin's Lymphoma


There is additional contact information available for James Lynch, but you are not authorized to see it. Use the LOGIN button inthe upper right of this page and you will be returned here after login.